Settlement Agreements, Prestigious Recognitions, Proposed M&A's, and Support for New Drug Candidates - Research Report on Teva, Aegerion, Community Health Systems, Air Methods and Vanda Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 28, 2013 NEW YORK, November 28, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries Limited (NYSE: TEVA), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Community Health Systems, Inc. (NYSE: CYH), Air Methods Corp. (NASDAQ: AIRM) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Teva Pharmaceutical Industries Limited Research Report On November 25, 2013, Teva Pharmaceuticals Industries Limited (Teva Pharmaceuticals) and Mylan Inc. jointly announced that certain of its affiliates have come to a settlement agreement and dismiss the pending patent litigation involving Copaxone in the United Kingdom, the Netherlands and France relating to non-infringement and the validity of European Patent 0,762,888, which expires in May 2015. The companies did not disclose the terms of the settlement. The Full Research Report on Teva Pharmaceutical Industries Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s=DDD http://www.analystscorner.com/r/full_research_report/e3a3_TEVA -- Aegerion Pharmaceuticals, Inc. Research Report On November 18, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that it has been named as one of the Top Places to Work in Boston in 2013 by the Boston Globe. The Company ranked 20th out of 115 in the small employer category (defined as companies with 50-99 Massachusetts-based employees). "Aegerion has experienced significant growth in the past year, and one of our top priorities is to maintain our employee-focused culture," said Marc D. Beer, CEO of Aegerion. "Having Aegerion employees elect the Company as a Top Place to Work is a source of great pride for our organization. This honor is a reflection of our dedicated employees who pursue our mission to treat patients with rare diseases." The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/a3f6_AEGR -- Community Health Systems, Inc. Research Report On November 22, 2013, Community Health Systems, Inc. (CHS) and Health Management Associates, Inc. (HMA) announced that the Registration Statement on Form S-4 relating to the companies' proposed merger has been declared effective by the Securities and Exchange Commission (SEC). "We are pleased that the SEC has completed its review, and we can continue to move towards the successful completion of our acquisition of HMA," said Wayne T. Smith, Chairman, President and CEO of CHS. "We continue to believe this transaction represents full and fair value for HMA stockholders, while positioning CHS for long-term growth that will generate incremental stockholder value and benefit local communities and patients around the country." The transaction is expected to be completed during Q1 2014 and is subject to approval of HMA stockholders holding 70% of HMA's outstanding shares, antitrust clearance, receipt of other regulatory approvals, and the absence of certain adverse developments. The Full Research Report on Community Health Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/7587_CYH -- Air Methods Corp. Research Report On November 18, 2013, Air Methods Corp. (Air Methods) announced that it has entered into a definitive agreement to acquire Blue Hawaiian Helicopters and its affiliates (Blue Hawaiian), a helicopter tour operator based in Hawaii. Commenting on the acquisition agreement, Aaron Todd, Air Methods' CEO, stated "the acquisition of Blue Hawaiian, when combined with Sundance Helicopters, our aerial tour operator acquired in December 2012, will position Air Methods Tours as the leading aerial tour provider in two of the most coveted tourism venues in the United States: the Las Vegas/Grand Canyon region and Hawaii." The transaction is expected to close in Q4 2013. The Full Research Report on Air Methods Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/ff38_AIRM -- Vanda Pharmaceuticals Inc. Research Report On November 15, 2013, Bloomberg reported that Vanda Pharmaceuticals Inc. (Vanda) has won the backing of U.S. advisers for an experimental drug known as tasimelteon, to regulate the circadian rhythms of blind people to help them sleep. According to the report, Food and Drug Administration said that Vanda's medicine is effective and safe for use. Further, Bloomberg stated that the medication, which the Company has proposed calling Hetlioz, is supposed to help synchronize the body with a 24-hour cycle. No other approved treatments exist for the condition called non-24-hour disorder, which affects about 80,000 totally blind people in the U.S., the report added. The FDA is expected to decide on whether to approve Vanda's drug by January 31, 2013. The Full Research Report on Vanda Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/b5ad_VNDA ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Settlement Agreements, Prestigious Recognitions, Proposed M&A's, and Support for New Drug Candidates - Research Report on Teva,
Press spacebar to pause and continue. Press esc to stop.